Interplay between demographic, clinical and polygenic risk factors for severe COVID-19.

Abstract

BackgroundWe aimed to identify clinical, socio-demographic and genetic risk factors for severe COVID-19 (hospitalization, critical care admission or death) in the general population.MethodsIn this observational study, we identified 9560 UK Biobank participants diagnosed with COVID-19 during 2020. A polygenic risk score (PRS) for severe COVID-19 was derived and optimized using publicly available European and trans-ethnic COVID-19 genome-wide summary statistics. We estimated the risk of hospital or critical care admission within 28 days or death within 100 days following COVID-19 diagnosis, and assessed associations with socio-demographic factors, immunosuppressant use and morbidities reported at UK Biobank enrolment (2006–2010) and the PRS. To improve biological understanding, pathway analysis was performed using genetic variants comprising the PRS.ResultsWe included 9560 patients followed for a median of 61 (interquartile range = 34–88) days since COVID-19 diagnosis. The risk of severe COVID-19 increased with age and obesity, and was higher in men, current smokers, those living in socio-economically deprived areas, those with historic immunosuppressant use and individuals with morbidities and higher co-morbidity count. An optimized PRS, enriched for single-nucleotide polymorphisms in multiple immune-related pathways, including the ‘oligoadenylate synthetase antiviral response’ and ‘interleukin-10 signalling’ pathways, was associated with severe COVID-19 (adjusted odds ratio 1.32, 95% CI 1.11–1.58 for the highest compared with the lowest PRS quintile).ConclusionThis study conducted in the pre-SARS-CoV-2-vaccination era, emphasizes the novel insights to be gained from using genetic data alongside commonly considered clinical and socio-demographic factors to develop greater biological understanding of severe COVID-19 outcomes.